CLINICAL EFFICACY OF BONE ALKALINE-PHOSPHATASE AND PROSTATE-SPECIFIC ANTIGEN IN THE DIAGNOSIS OF BONE METASTASIS IN PROSTATE-CANCER

Purpose: We investigated the usefulness of bone alkaline phosphatase i soenzyme and prostate specific antigen (PSA) determined by radioimmuno assay to predict bone scan evidence of metastasis in newly diagnosed u ntreated and treated prostate cancer. Materials and Methods: We analyz ed bone alkaline phosphatase enzyme concentrations in 350 men, includi ng 150 controls, 100 with benign prostatic hyperplasia and 100 with pr ostate cancer (52 with stages T1 to 4, MO and 48 with stages T1 to 4, M1 to 4). We also analyzed bone alkaline phosphatase enzyme concentrat ions in 61 stages T1 to 4, MO prostate cancer cases during followup af ter radical prostatectomy or hormonal therapy, and 17 had clinical pro gression (9 with local, 5 with lymph node and 3 with bone metastases). Simultaneously, we analyzed PSA concentrations. Results: Average bone alkaline phophatase enzyme levels were 12, 11.1 and 10.0 ng./ml. in t he control, benign prostatic hyperplasia and stage MO prostate cancer groups, respectively (p not significant), and 83.2 ng./ml. in patients with stage M1 to 4 disease (p < 0.001). Considering that to diagnose bone metastasis the cutoff for bone alkaline phosphatase enzyme and PS A is 30 ng./ml. and 100 ng./ml., respectively, clinical effectiveness was 93.7% and 81.8%, respectively. Finally, measurement of both substa nces at:the same time increased clinical effectiveness to 97.9%. Durin g followup a bone alkaline phosphatase enzyme level that becomes great er than 30 ng./ml. (0% in the local and lymphatic progression groups, and 100% in the bone metastasis group) indicates the need to perform a bone scan. Conclusions: We recommend the clinical use of bone alkalin e phosphatase enzyme determined by radioimmunoassay and PSA measuremen t for the diagnosis of bone metastases and progression of prostate can cer because of the good sensitivity and specificity.